MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix: Reports, Publications & Metrics
Triple Helix: Regional Innovation Clusters (RIC)s
Intermediaries: Triple Helix Regional Innovation Clusters (RIC)s
RICS (Regional Innovation Clusters) - Medical, Life Sciences & Emerging Technology Hotspots
*Industry: Ireland
Celgene (NASDAQ: CELG)
Finance & Acquisitions: Celgene
Acetylon Pharmaceuticals
Organization & Developments: Acetylon
Parents
Acetylon Pharmaceuticals
Children
Acetylon Pharmaceuticals, Inc. is applying its unique capabilities to discover and develop next-generation, highly selective small molecule drugs to realize the therapeutic potential of HDAC inhibition to treat cancer, autoimmune and other diseases, while
Blood cancers such as multiple myeloma are characterized by successive genetic mutations resulting in rapid cell proliferation and excess production of intracellular proteins.
Clinical-stage developer of selective deacetylase enzyme inhibitors focused on multiple myeloma
The proceeds will be used in part to fund the advancement of the Company’s lead drug candidate ACY-1215 – a next-generation Class II-selective histone deacetylase (HDAC) inhibitor – into Phase I/II clinical testing for patients with relapsed and relapsed-r
Jumps
*Key People: Acetlyon
Finance & Acquisitions: Acetylon